Hiance Anne, Chevret Sylvie, Lévy Vincent
INSERM 9504, Centre d'Investigations Cliniques, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Université Paris 7, France.
J Clin Epidemiol. 2009 Apr;62(4):431-437.e2. doi: 10.1016/j.jclinepi.2008.04.009. Epub 2008 Nov 17.
To propose and compare practical approaches that allow eliciting and using expert opinions about the benefit effect on a censored endpoint, such as event-free survival (EFS), used in the planning of a clinical trial based on Bayesian methodology.
Individual interviews of 37 experts. Bayesian normal models on the log hazard ratio (HR) of EFS were implemented. We illustrate our approach by using a trial of autologous stem cell transplantation (ASCT) vs. chemotherapy (CT) in chronic lymphocytic leukemia (CLL). We elicited experts' prior beliefs about the difference in 3-year EFS between the two treatment arms, either roughly or throughout weights over the difference scale. Subsequently, a Bayesian synthesis of the information reported in the trial protocol with that in the experts' prior was performed, using: (1) the postulated treatment effect based on null (skeptical) and alternative (enthusiastic) hypotheses with shared standard error; and (2) the expected difference derived from experts' distributions.
As compared with the priors based on the trial protocol data, expert priors agreed with some average from enthusiastic and skeptical information, with close standard errors.
This case study illustrates a rational approach to construct an expert-based prior. It should be considered as part of the design of future Bayesian trials.
提出并比较实用的方法,这些方法能够引出并利用专家对审查终点(如无事件生存期(EFS))的益处效应的意见,该审查终点用于基于贝叶斯方法的临床试验规划。
对37位专家进行个人访谈。实施了关于EFS对数风险比(HR)的贝叶斯正态模型。我们通过一项慢性淋巴细胞白血病(CLL)中自体干细胞移植(ASCT)与化疗(CT)对比试验来说明我们的方法。我们引出了专家对于两个治疗组3年EFS差异的先验信念,无论是大致的还是在差异尺度上的整体权重。随后,使用以下方法对试验方案中报告的信息与专家先验信息进行贝叶斯综合:(1)基于零假设(怀疑)和备择假设(热情)且具有共享标准误差的假定治疗效果;(2)从专家分布得出的预期差异。
与基于试验方案数据的先验相比,专家先验与来自热情和怀疑信息的某个平均值一致,且标准误差相近。
本案例研究说明了构建基于专家的先验的合理方法。它应被视为未来贝叶斯试验设计的一部分。